Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2021. Read More.
Open Access Percentage
64%
Total
Publications
513
Total Open
Publications
329
Total
Citations
49K
Open Access
Percentage
64%
Total
Publications
513
Total Open
Publications
329
Total
Citations
49K
Breakdown
Publisher Open
15%
Both
36%
Other Platform Open
13%
Closed
36%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 31%
81
Hybrid 31%
81
No Guarantees 38%
98
Other Platform Open
Domain 89%
225
Institution 28%
72
Other Internet 8%
21
Public 8%
20
Preprint 7%
18
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 224 |
Europe PMC | Domain | 193 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 24 |
Semantic Scholar | Public | 19 |
Harvard University - Digital Access to Scholarship at Harvard (DASH) | Institution | 14 |
DOI | Other Internet | 13 |
University College London - UCL Discovery | Institution | 11 |
bioRxiv | Preprint | 10 |
medRxiv | Preprint | 7 |
King's College London - Research Portal | Institution | 6 |